441 related articles for article (PubMed ID: 6690034)
21. Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
Rosowsky A; Kim SH; Ross J; Wick MM
J Med Chem; 1982 Feb; 25(2):171-8. PubMed ID: 7057424
[TBL] [Abstract][Full Text] [Related]
22. 1-beta-D-arabinofuranosylcytosine conjugates of ether and thioether phospholipids. A new class of ara-C prodrug with improved antitumor activity.
Hong CI; West CR; Bernacki RJ; Tebbi CK; Berdel WE
Lipids; 1991 Dec; 26(12):1437-44. PubMed ID: 1819747
[TBL] [Abstract][Full Text] [Related]
23. Influence of 1-beta-D-arabinofuranosylcytosine conjugates of lipids on the growth and metastasis of Lewis lung carcinoma.
Berdel WE; Danhauser S; Hong CI; Schick HD; Reichert A; Busch R; Rastetter J; Vogler WR
Cancer Res; 1988 Feb; 48(4):826-9. PubMed ID: 3338080
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
25. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
Maehara Y; Kusumoto T; Sakaguchi Y; Kusumoto H; Anai H; Sugimachi K
Anticancer Res; 1989; 9(1):41-4. PubMed ID: 2705754
[TBL] [Abstract][Full Text] [Related]
27. Enzyme catalyzation of the deacylation of N4-acyl derivatives of 1-beta-D-arabinofuranosylcytosine in the mouse liver microsome.
Tsuruo T; Hori K; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Jun; 42(6):2250-4. PubMed ID: 7074607
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
[TBL] [Abstract][Full Text] [Related]
29. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
30. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
Ellens H; Rustum Y; Mayhew E; Ledesma E
J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321
[TBL] [Abstract][Full Text] [Related]
32. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
33. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
Takenaka T; Kimura K
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176
[No Abstract] [Full Text] [Related]
34. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
Cass CE; Muzik H; Paterson AR
Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159).
McGovren JP; Neil GL; Crampton SL; Robinson MI; Douros JD
Cancer Res; 1977 Jun; 37(6):1666-72. PubMed ID: 870180
[TBL] [Abstract][Full Text] [Related]
37. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Dawson KM
Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
[TBL] [Abstract][Full Text] [Related]
38. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
Kataoka T; Sakurai Y
Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
[TBL] [Abstract][Full Text] [Related]
39. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
[TBL] [Abstract][Full Text] [Related]
40. 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs.
Hong CI; Kirisits AJ; Buchheit DJ; Nechaev A; West CR
Cancer Drug Deliv; 1986; 3(2):101-13. PubMed ID: 3708534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
